ArticleBMC gastroenterology2026
Fusobacterium nucleatum exacerbates chronic atrophic gastritis in rats via mitochondrial dysfunction and inflammatory activation.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic atrophic gastritis (CAG) is a premalignant condition with limited therapeutic strategies. The role of the oral pathogen Fusobacterium nucleatum (F. nucleatum), associated with gastrointestinal carcinogenesis, in CAG remains unclear.
methodsThis study investigated whether F. nucleatum aggravates gastric mucosal injury through inflammation and mitochondrial dysfunction in CAG. A rat model of CAG was induced using N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) for 10 weeks, combined with oral gavage of F. nucleatum. Gastric pathology, bacterial colonization, serum cytokine levels, and mitochondrial membrane potential were evaluated. In vitro, human gastric epithelial cells (GES-1) were treated with MNNG and co-cultured with F. nucleatum at multiplicities of infection (MOI) of 50, 100, or 150. Cytokine concentrations in cell culture supernatants were quantified using corresponding human enzyme-linked immunosorbent assay kits. Mitochondrial membrane potential was assessed via flow cytometry.
resultsF. nucleatum colonized gastric tissues and intensified MNNG-induced injury, including rugal flattening, glandular atrophy, intestinal metaplasia, and inflammatory cell infiltration. It significantly increased pro-inflammatory cytokine levels and further decreased mitochondrial membrane potential. In GES-1 cells, F. nucleatum dose-dependently elevated secretion of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) and impaired mitochondrial function.
conclusionsF. nucleatum exacerbates CAG by promoting gastric inflammation and mitochondrial dysfunction. These findings may underscore the microbiota-mitochondria axis as a potential therapeutic target to prevent CAG progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.